3M and MIT Researchers Developing a Rapid Diagnostic Test for COVID-19 Duplicate 1 - CIMIT MAIN
We are thrilled to announce that we’ve been selected as one of the first spokes of the ARPA-H Investor Catalyst Hub network!
We are excited to be a part of this nationwide network dedicated to accelerating groundbreaking advances in science and medicine—all in pursuit of better health outcomes for everyone.
Learn more >
Funding Opportunities and Events
NIH Rapid Acceleration of Diagnostics Technology (RADx® Tech) Fetal Monitoring Challenge
$2 million in prizes to accelerate the development of diagnostic and monitoring technologies to reduce the risk of fetal morbidity and mortality and thus improve fetal and neonatal health outcomes.
Read More »
Research and Innovation Translation Partnerships in Point-of-Care Technologies Conference and Technology Showcase
A two-day conference with researchers, technology developers, clinicians, and industry partners.
Read More »
News and Annoucements
3M and MIT Researchers Developing a Rapid Diagnostic Test for COVID-19
The goal is a new, highly accurate, mass-produced low-cost diagnostic device that delivers results in minutes.
ST. PAUL, Minn.--(BUSINESS WIRE)--To help the world respond to COVID-19, 3M and researchers at MIT are testing a new rapid test that detects the virus. Accelerated research is underway to learn if a simple-to-use, diagnostic device can produce highly accurate results within minutes and is feasible to mass manufacture.
The U.S. National Institute of Health selected the rapid COVID-19 test for accelerated development and commercialization support, after rigorous review by an expert panel. The test is in the Rapid Acceleration of Diagnostics Tech (RADx Tech) program, an aggressively-paced COVID-19 diagnostics initiative from the NIH’s National Institute of Biomedical Imaging and Bioengineering.
Connect with Us
Our Lasting Impact
As an early pioneer in managing translational research, CIMIT has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.
We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.
We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.